Lorenzo Gerratana, Associate Professor of Medicine and Scientific Lead for Breast Medical Oncology at the CRO Aviano National Cancer Institute and the University of Udine, shared a post on LinkedIn:
“Fresh out of the press!
Together with leading international clinicians and translational researchers in the liquid biopsy field, we reached consensus on the current and future clinical integration of circulating tumor cells (CTCs) across solid tumors.
Key takeaways:
- Established clinical utility in metastatic breast and prostate cancers
- Investigational role in other solid tumors, awaiting prospective validation
- Early breast cancer highlighted as a key frontier, especially in combination with cfDNA for minimal residual disease detection
- Call for standardization, platform harmonization, and clinician education
- The future lies in molecular characterization and integrated liquid biopsy approaches
Beyond enumeration, CTCs are increasingly viewed as living biomarkers, bringing us closer to real-time, patient-specific cancer monitoring.”
Title: International expert consensus on the clinical integration of circulating tumor cells in solid tumors
Authors: Eleonora Nicolò, Carolina Reduzzi, Jean-Yves Pierga, Paola Gazzaniga, Nikolas H. Stoecklein, Valeria Denninghoff, Dominic G. Rothwell, Johann S. De Bono, Dario Marchetti, Evi Lianidou, Sabine Riethdorf, Daniele Generali, Paul Hofman, Lorenzo Gerratana, Peter Kuhn, Jean Paul Thiery, Michail Ignatiadis, Francois-Clement Bidard, Anthony Lucci, Sabine Kasimir-Bauer, Maria Jose Serrano, Massimo Cristofanilli
Read the Full Article.
